Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-05
DOI
10.3389/fimmu.2021.720571
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications
- (2019) Sandra P. Susanibar Adaniya et al. AMERICAN JOURNAL OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
- (2019) Eric L. Smith et al. Cancer Immunology Research
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
- (2019) Meral Beksac et al. HAEMATOLOGICA
- Extramedullary multiple myeloma
- (2019) Manisha Bhutani et al. LEUKEMIA
- Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
- (2019) Naoki Hosen Cancers
- Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
- (2018) Nico Gagelmann et al. HAEMATOLOGICA
- Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
- (2018) Meletios Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
- (2018) Nico Gagelmann et al. HAEMATOLOGICA
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Cytokine release syndrome: grading, modeling, and new therapy
- (2018) Delong Liu et al. Journal of Hematology & Oncology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
- (2017) Arnab Ghosh et al. LEUKEMIA & LYMPHOMA
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- How I treat high-risk myeloma
- (2015) S. Lonial et al. BLOOD
- How I treat extramedullary myeloma
- (2015) C. Touzeau et al. BLOOD
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
- (2013) L. Pour et al. HAEMATOLOGICA
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
- (2012) S. Z. Usmani et al. HAEMATOLOGICA
- Extramedullary multiple myeloma
- (2012) Matthew Weinstock et al. LEUKEMIA & LYMPHOMA
- Multiple myeloma with extramedullary disease
- (2011) Albert Oriol ADVANCES IN THERAPY
- Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
- (2011) Joan Bladé et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
- (2009) M. Varettoni et al. ANNALS OF ONCOLOGY
- Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome
- (2008) M C Minnema et al. BONE MARROW TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now